MTPConnect, the industry growth centre set up to champion the Australian medtech sector will match $1m of funding for Covid19 related research efforts.
The third round of its Biomedical Translation Bridge (BTB) program aims to support small and medium enterprises, medical research institutes and universities conducting COVID-19 related research projects.
“Our program will support medical devices and diagnostics research, prophylactic development – such as vaccines – and therapeutic approaches that will make an impact in 12-months or less” said MTPConnect Managing Director, Dr Dan Grant.
“Speed is of the essence so applications will only be open for two weeks from Monday 18 May via a straightforward expression of interest process” he added.
MTPConnect has designed the rapid COVID-19 round to get results as quickly as possible to help protect the health of Australians and others around the world with the earliest possible deployment of new vaccines, therapeutics and devices.
“By supporting the translation and commercialisation of Australian research know-how, MTPConnect is backing the creation of in-demand health products that can be deployed around the world and the creation of new jobs which will be so critical to the post-COVID-19 recovery,” Dr Grant says.
The BTB program is an initiative of the Australian Government’s Medical Research Future Fund that is operated by MTPConnect and delivered in partnership with BioCurate, UniQuest, the Medical Device Partnering Program and QUT’s Bridge and BridgeTech programs.
Expressions of Interest open on Monday 18 May 2020 and close on Monday 1 June 2020. Details can be found at the BTB page.